References
1. Harris AM, Hicks LA, Qaseem A. Appropriate antibiotic use for acute respiratory tract infection in adults: advice for high-value care from the American College of Physicians and the Centers for Disease Control and Prevention. Annals of Internal Medicine 2016;164:425-34.
2. Ai T, Yang Z, Hou H, et al. Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases. Radiology 2020:200642.
3. Li D, Wang D, Dong J, et al. False-negative results of real-time reverse-transcriptase polymerase chain reaction for severe acute respiratory syndrome coronavirus 2: role of deep-learning-based CT diagnosis and insights from two cases. Korean journal of radiology 2020;21:505-8.
4. Xie X, Zhong Z, Zhao W, Zheng C, Wang F, Liu J. Chest CT for typical 2019-nCoV pneumonia: relationship to negative RT-PCR testing. Radiology 2020:200343.
5. Fang Y, Zhang H, Xie J, et al. Sensitivity of chest CT for COVID-19: comparison to RT-PCR. Radiology 2020:200432.
6. Wölfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized patients with COVID-2019. Nature 2020:1-5.
7. Wang W, Xu Y, Gao R, et al. Detection of SARS-CoV-2 in different types of clinical specimens. Jama 2020.
8. Zhao J, Yuan Q, Wang H, et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. 2020.
9. Long C, Xu H, Shen Q, et al. Diagnosis of the Coronavirus disease (COVID-19): rRT-PCR or CT? European journal of radiology 2020:108961.
10. Sun Y, Koh V, Marimuthu K, et al. Epidemiological and clinical predictors of COVID-19. Clinical Infectious Diseases 2020.
11. Woloshin S, Patel N, Kesselheim AS. False Negative Tests for SARS-CoV-2 Infection—Challenges and Implications. New England Journal of Medicine 2020.
12. Kucirka LM, Lauer SA, Laeyendecker O, Boon D, Lessler J. Variation in False-Negative Rate of Reverse Transcriptase Polymerase Chain Reaction–Based SARS-CoV-2 Tests by Time Since Exposure. Annals of Internal Medicine 2020.
13. Pulia MS, O’Brien TP, Hou PC, Schuman A, Sambursky R. Multi-Tiered Screening and Diagnosis Strategy for COVID-19: A Model for Sustainable Testing Capacity in Response to Pandemic. Annals of Medicine 2020:1-20.
14. Dahler-Eriksen BS, Lauritzen T, Lassen JF, Lund ED, Brandslund I. Near-patient test for C-reactive protein in general practice: assessment of clinical, organizational, and economic outcomes. Clinical chemistry 1999;45:478-85.
15. Diederichsen HZ, Skamling M, Diederichsen A, et al. Randomised controlled trial of CRP rapid test as a guide to treatment of respiratory infections in general practice. Scandinavian journal of primary health care 2000;18:39-43.
16. Hansson LO, Carlsson I, Hansson E, Hovelius B, Svensson P, Tryding N. Measurement of C-reactive protein and the erythrocyte sedimentation rate in general practice. Scandinavian journal of primary health care 1995;13:39-45.
17. Hopstaken RM, Muris JW, Knottnerus JA, Kester AD, Rinkens PE, Dinant GJ. Contributions of symptoms, signs, erythrocyte sedimentation rate, and C-reactive protein to a diagnosis of pneumonia in acute lower respiratory tract infection. The British journal of general practice : the journal of the Royal College of General Practitioners 2003;53:358-64.
18. Lindback S, Hellgren U, Julander I, Hansson LO. The value of C-reactive protein as a marker of bacterial infection in patients with septicaemia/endocarditis and influenza. Scandinavian Journal of Infectious Diseases 1989;21:543-9.
19. McCarthy PL, Frank AL, Ablow RC, Masters SJ, Dolan TF, Jr. Value of the C-reactive protein test in the differentiation of bacterial and viral pneumonia. The Journal of pediatrics 1978;92:454-6.
20. Salonen EM, Vaheri A. C-reactive protein in acute viral infections. Journal of medical virology 1981;8:161-7.
21. Thompson D, Whicher JT, Banks RE. Acute phase reactants in predicting disease outcome. Bailliere’s Clinical Rheumatology 1992;6:393-404.
22. Young B, Gleeson M, Cripps AW. C-reactive protein: a critical review. Pathology 1991;23:118-24.
23. Goodbourn S, Didcock L, Randall RE. Interferons: cell signalling, immune modulation, antiviral response and virus countermeasures. Journal of General Virology 2000;81:2341-64.
24. Shapiro NI, Self WH, Rosen J, et al. A prospective, multi-centre US clinical trial to determine accuracy of FebriDx point-of-care testing for acute upper respiratory infections with and without a confirmed fever. Annals of medicine 2018;50:420-9.
25. Self WH, Rosen J, Sharp SC, et al. Diagnostic accuracy of FebriDx: a rapid test to detect immune responses to viral and bacterial upper respiratory infections. Journal of clinical medicine 2017;6:94.
26. Sambursky R, Shapiro N. Evaluation of a combined MxA and CRP point-of-care immunoassay to identify viral and/or bacterial immune response in patients with acute febrile respiratory infection. European clinical respiratory journal 2015;2:28245.
27. Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. Asian Pacific J allergy Immunol 2020;10.
28. Tynell J, Westenius V, Rönkkö E, et al. Middle East respiratory syndrome coronavirus shows poor replication but significant induction of antiviral responses in human monocyte-derived macrophages and dendritic cells. The Journal of general virology 2016;97:344.
29. The Centers for Disease Control and Prevention (CDC). Evaluating and Testing Persons for Coronavirus Disease 2019 (COVID-19). Centers for Disease Control and Prevention, 2020. (Accessed April 1, 2020, at https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-criteria.html.)
30. The Centers for Disease Control and Prevention (CDC). Coronavirus Disease 2019 (COVID-19): 2020 Interim Case Definition, Approved April 5, 2020 2020.
31. Public Health England (PHE). Guidance COVID-19: investigation and initial clinical management of possible cases 2020.
32. Public Health England (PHE). Guidance COVID-19: investigation and initial clinical management of possible cases 2020.
33. Schuetz P, Christ-Crain M, Thomann R, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA 2009;302:1059-66.
34. National Clinical Guideline C. Pneumonia: Diagnosis and management of community and hospital acquired pneumonia in Adults. Clin Guidel 2014.
35. Docherty AB, Harrison EM, Green CA, et al. Features of 16,749 hospitalised UK patients with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol. medRxiv 2020:2020.04.23.20076042.
36. Brendish NJ, Poole S, Naidu VV, et al. Real-World Diagnostic Accuracy of a Host Response Point-of-Care Test in Hospitalised Patients with Suspected COVID-19. Available at SSRN 3582747 2020.
37. Clark T, Brendish N. Evaluating the clinical impact of routine molecular point-of-care testing for COVID-19 in adults presenting to hospital: A prospective, interventional, non-randomised pre and post implementation study (CoV-19POC)[Protocol]. 2020.
Table 1. Cohort Characteristics